search
Back to results

rTMS in Wilson Disease Dysarthria (WILSTIM2)

Primary Purpose

Wilson Disease

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
rTMS
Sham stimulation
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Wilson Disease focused on measuring dyasarthria, repetitive transcranial magnetic stimulation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Conseting adult patients with social insurance
  • Wilson disease with dystonic hyperkinetic dysarthria
  • Stable pharmacological therapy n the last 6 monts
  • Brain MRI in the previous 6 months, without additional brain lesion
  • Patients that did not receive botulinium toxin in the previous 4 months

Exclusion Criteria:

  • Incapacitated adult
  • Previous mdedical history of epilepsia
  • Pregnancy or breastfeeding
  • Brain lesion outside basal ganglia on brain MRI
  • Patient consider by the investigator not able to sustain an 30 minutes rTMS session without moving
  • Vocal chord lesion
  • Previous history of laryngeal surgery
  • rTMS contra indication

Sites / Locations

  • Service de Physiologie Clinique-Explorations Fonctionnelles, AP-HP, Hôpital Lariboisière
  • Service de Neurologie, Hopital Fondation Adolphe de RothschildRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Experimental stimulation

Sham stimulation

Arm Description

Patients receive an inhibitor treatment of rTMS using activ coil (MCF B65 coil) for 30 minutes at 1Hz at 80% of the resting motor threshold (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).

Patients receive a treatment of rTMS using placebo coil (MCF P B65 coil) for 30 minutes at 1Hz (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).

Outcomes

Primary Outcome Measures

Improvement of the Clinical Assessment Battery for Dysarthria intelligibility score
Improvement of the Clinical Assessment Battery for Dysarthria intelligibility score with active stimulation in comparison to sham stimulation

Secondary Outcome Measures

Improvement of the Clinical Assessment Battery for Dysarthria intelligibility sub-scores
Improvement of the Clinical Assessment Battery for Dysarthria intelligibility sub-scores with active stimulation in comparison to sham stimulation
the "A" phonation time
Improvement of the "A" phonation time with active stimulation in comparison to sham stimulation
Improvement of the diadococinesia
Improvement of the diadococinesia with active stimulation in comparison to sham stimulation
Improvement of text reading
Improvement of text reading with active stimulation in comparison to sham stimulation
Improvement of bucco-linguo-facial motricity
Improvement of bucco-linguo-facial motricity with active stimulation in comparison to sham stimulation
Improvement bucco-linguo-facial motricity
Improvement bucco-linguo-facial motricity with active stimulation in comparison to sham stimulation
Correlation between clinical Assessment Battery for Dysarthria intelligibility score and UWDRS, and MRI brain atrophy and basal ganglia lesions
Correlation of changes in the Battery for Dysarthria intelligibility score with clinical parameters (age at diagnosis, delay related to first symptoms, degree of neurological handicap and brain lesions observed on basline MRI (cortical atrophy and lesions of the basal ganglia)
Side effects of rTMS
Any side effect after stimulation (fatigue, neck pain, neck stiffness, dizziness, nausea, itching, mood disorders ..) will be collected following the stimulation. Side effects of rTMS are rare. Most often they are minor and transient.

Full Information

First Posted
May 14, 2021
Last Updated
March 28, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT04910581
Brief Title
rTMS in Wilson Disease Dysarthria
Acronym
WILSTIM2
Official Title
Inhibitory rTMS Applied on Laryngeal Motor Cortex in Wilson's Disease Patients With Dysarthria
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 23, 2023 (Actual)
Primary Completion Date
January 23, 2024 (Anticipated)
Study Completion Date
February 23, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Wilson disease is a hereditary hepatic and neurological disease associated with copper accumulation. Neurological symptoms are of extra-pyramidal, cerebellar and dystonic origin. Dysarthria is one of the debilitating symptoms of Wilson disease poorly responsive to pharmacological treatment. The most common form is a dystonic hyperkinetic Dysarthria. Pathophysiology of dystonia is still not elucidated. Motor cortex hyperexcitability has been demonstrated in various forms of dystonia. Furthermore, rTMS inhibitory applied over motor cortex has been shown to transitory reduce dystonic symptoms in various forms of dystonia. In the present study, we investigate the effect of a single 1Hz 20-minutes inhibitory rTMS session applied over the motor laryngeal cortex on dyasarthria is the main kinetic dysarthria has been shown to be associated with inhibition of laryngeal motor cortex in Parkinson disease.
Detailed Description
A consecutive series of Wilson disease patients with dystonic hyperkinetic dysarthria will be prospectively recruited. Patients will receive 3 days apart to two rTMS sessions. rTMS procedures will be performed with a figure of eight coiled. A single 20-minutes 1 Hz biphasic stimulation (1200 pulses) session will be applied over the laryngeal motor cortex. A brain imaging positioning device will be used during all the procedure A second stimulation session will be performed 3 days apart. Patients will be centrally randomized to receive first either the active stimulation (80% of the resting motor threshold) or the sham stimulation (using a visually identical coil to reproduce the click sound and the scalp sensation of the active coil). A TMS evaluation of cortical silent period over the left motor cortex will be performed before the first rTMS session. Before and immediately after each stimulation (active or sham) patient will received an clinical evaluation including Clinical Assessment Battery for Dysarthria intelligibility score, "A" phonation time, diadococinesia , bucco-linguo-facial motricity score and UWDRS. A standard 20-minutes EEG will be performed before the first rTMS session and immediately after the second rTMS session.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wilson Disease
Keywords
dyasarthria, repetitive transcranial magnetic stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
After randomization, patients are to receive blindly the first rTMS session according to the arm (placebo or active). A second stimulation session is to be performed 3 days apart to apply the reverse arm.
Masking
ParticipantOutcomes Assessor
Masking Description
Patients are centrally randomized to receive first either the active stimulation (80% of the resting motor threshold) or the sham stimulation (using a visually identical coil to reproduce the click sound and the scalp sensation of the active coil). The operator is unblided. The evaluator is blinded.
Allocation
Randomized
Enrollment
18 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental stimulation
Arm Type
Active Comparator
Arm Description
Patients receive an inhibitor treatment of rTMS using activ coil (MCF B65 coil) for 30 minutes at 1Hz at 80% of the resting motor threshold (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).
Arm Title
Sham stimulation
Arm Type
Placebo Comparator
Arm Description
Patients receive a treatment of rTMS using placebo coil (MCF P B65 coil) for 30 minutes at 1Hz (MagPro stimulator; MagVenture A / S, Farum, Denmark) onto the left laryngeal cortex located thanks to a neuronavigation device (Syneika one [SYN1], Syneika, Cesson-Sévigné, France).
Intervention Type
Procedure
Intervention Name(s)
rTMS
Intervention Description
Single 30-minutes session of 1Hz rTMS applied over the left laryngeal motor cortex
Intervention Type
Procedure
Intervention Name(s)
Sham stimulation
Intervention Description
Single 30-minutes session of sham stimulation applied over the left laryngeal motor cortex
Primary Outcome Measure Information:
Title
Improvement of the Clinical Assessment Battery for Dysarthria intelligibility score
Description
Improvement of the Clinical Assessment Battery for Dysarthria intelligibility score with active stimulation in comparison to sham stimulation
Time Frame
within 30 minutes after stimulation session at Day1 and Day4
Secondary Outcome Measure Information:
Title
Improvement of the Clinical Assessment Battery for Dysarthria intelligibility sub-scores
Description
Improvement of the Clinical Assessment Battery for Dysarthria intelligibility sub-scores with active stimulation in comparison to sham stimulation
Time Frame
within 30 minutes after stimulation session at Day1 and Day4
Title
the "A" phonation time
Description
Improvement of the "A" phonation time with active stimulation in comparison to sham stimulation
Time Frame
within 30 minutes after stimulation session at Day1 and Day4
Title
Improvement of the diadococinesia
Description
Improvement of the diadococinesia with active stimulation in comparison to sham stimulation
Time Frame
within 30 minutes after stimulation session at Day1 and Day4
Title
Improvement of text reading
Description
Improvement of text reading with active stimulation in comparison to sham stimulation
Time Frame
within 30 minutes after stimulation session at Day1 and Day4
Title
Improvement of bucco-linguo-facial motricity
Description
Improvement of bucco-linguo-facial motricity with active stimulation in comparison to sham stimulation
Time Frame
within 30 minutes after stimulation session at Day1 and Day4
Title
Improvement bucco-linguo-facial motricity
Description
Improvement bucco-linguo-facial motricity with active stimulation in comparison to sham stimulation
Time Frame
within 30 minutes after stimulation session at Day1 and Day4
Title
Correlation between clinical Assessment Battery for Dysarthria intelligibility score and UWDRS, and MRI brain atrophy and basal ganglia lesions
Description
Correlation of changes in the Battery for Dysarthria intelligibility score with clinical parameters (age at diagnosis, delay related to first symptoms, degree of neurological handicap and brain lesions observed on basline MRI (cortical atrophy and lesions of the basal ganglia)
Time Frame
at Day1 and Day4
Title
Side effects of rTMS
Description
Any side effect after stimulation (fatigue, neck pain, neck stiffness, dizziness, nausea, itching, mood disorders ..) will be collected following the stimulation. Side effects of rTMS are rare. Most often they are minor and transient.
Time Frame
within few hours after stimulation session at Day1 and Day4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Conseting adult patients with social insurance Wilson disease with dystonic hyperkinetic dysarthria Stable pharmacological therapy n the last 6 monts Brain MRI in the previous 6 months, without additional brain lesion Patients that did not receive botulinium toxin in the previous 4 months Exclusion Criteria: Incapacitated adult Previous mdedical history of epilepsia Pregnancy or breastfeeding Brain lesion outside basal ganglia on brain MRI Patient consider by the investigator not able to sustain an 30 minutes rTMS session without moving Vocal chord lesion Previous history of laryngeal surgery rTMS contra indication
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pierre LOZERON, Md, PHD
Phone
+33(0) 1 49 95 80 76
Email
Pierre.lozeron@aphp.fr
Facility Information:
Facility Name
Service de Physiologie Clinique-Explorations Fonctionnelles, AP-HP, Hôpital Lariboisière
City
Paris
ZIP/Postal Code
75010
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre Lozeron, Md, PHD
Phone
+33(0) 1 49 95 80 76
Email
pierre.lozeron@aphp.fr
Facility Name
Service de Neurologie, Hopital Fondation Adolphe de Rothschild
City
Paris
ZIP/Postal Code
75019
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aurelia Poujois, Md
Phone
+33(0)1 48 03 66 56
Email
apoujois@for.paris

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

rTMS in Wilson Disease Dysarthria

We'll reach out to this number within 24 hrs